Discovery of Novel Sulfonylurea NLRP3 Inflammasome Inhibitor for the Treatment of Multiple Inflammatory Diseases
Journal of Medicinal Chemistry · 10.04.2025 · 68 (7) · 7243-7262
DOI: 10.1021/acs.jmedchem.4c02813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.03.2025. Verfasst von Yiting Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Sulfonylurea Compounds, Drug Discovery. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, Chinese Academy of Sciences.
Abstract (Originalsprache)
NLRP3 inflammasome is critical in innate immunity and inflammatory responses. A series of novel sulfonylurea-based NLRP3 inflammasome inhibitors was designed and synthesized. Notably, compound 15 exhibited the potent NLRP3 inhibitory activity, effectively suppressing IL-1β secretion in THP-1 (IC50 = 23 nM), demonstrating better efficacy compared to MCC950. It selectively inhibits NLRP3 activation by disrupting inflammasome assembly, with no effect on NLRC4 or AIM2 inflammasomes. Molecular docking showed that the 1-methyl-4-(methylamino)piperidine moiety forms a novel hydrogen bond with Asp662 in the hydrophilic region of NLRP3. Additionally, compound 15 displayed excellent pharmacokinetic properties with 99.6% oral bioavailability in mice. It exhibited superior efficacy in acute peritonitis and diabetic kidney disease models, surpassing MCC950. Tissue distribution studies confirmed that compound 15 specifically targeted the gut and showed efficacy in an IBD model, comparable to MCC950. These findings highlight compound 15 as a promising lead for novel oral NLRP3 inflammasome inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Lingang Laboratory, Shanghai 200031, China.
ORCID-Profile: Hong Liu, Jiang Wang
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Program of Shanghai Academic Research Leader
- Lingang Laboratory
Zitieren
APA
Liu, Y., Wang, Q., Ma, J., Li, J., Li, C., Xie, X., Xiao, Q., Xie, C., Liu, H., Hong, Y., & Wang, J. (2025). Discovery of Novel Sulfonylurea NLRP3 Inflammasome Inhibitor for the Treatment of Multiple Inflammatory Diseases. Journal of Medicinal Chemistry, 68(7), 7243-7262. https://doi.org/10.1021/acs.jmedchem.4c02813
Vancouver
Liu Y, Wang Q, Ma J, Li J, Li C, Xie X, et al. Discovery of Novel Sulfonylurea NLRP3 Inflammasome Inhibitor for the Treatment of Multiple Inflammatory Diseases. Journal of Medicinal Chemistry. 2025;68(7):7243-7262. doi:10.1021/acs.jmedchem.4c02813
BibTeX
@article{Liu2025,
author = {Liu, Yiting and Wang, Qinxue and Ma, Jinyu and Li, Jiyuan and Li, Cuina and Xie, Xiong and Xiao, Qiannan and Xie, Cen and Liu, Hong and Hong, Ying and Wang, Jiang},
title = {Discovery of Novel Sulfonylurea NLRP3 Inflammasome Inhibitor for the Treatment of Multiple Inflammatory Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {7},
pages = {7243--7262},
doi = {10.1021/acs.jmedchem.4c02813}
}
EUVIMED